Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
A new Penn Medicine preclinical study in Cell, "Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade," suggests that an existing drug known as a JAK in
Read moreReengineering Chimeric Antigen Receptor T Cells for Targeted Therapy of Autoimmune Disease
In a Science study with potentially major implications for the future treatment of autoimmunity and related conditions, co-senior author
Read moreScience Paper Describes Reengineered Chimeric Antigen Receptor T Cells for Targeted Therapy of Autoimmune Disease
Application could open up anti-cancer CAR approach to treatment for a much wider range of diseases, including autoimmunity and transplant rejection.
Read moreDouble Targeted CAR-T Scores in Preclinical Cancer Study for Solid Tumors
Paper in Immunity describes CAR T-Cells' effectiveness in mouse models of pancreatic cancer.
Read moreClinical Trial for Personalized Immunotherapy in Glioblastoma
Results from nine patients with brain tumor reported at AACR.
Read moreClinical Research Awards for Studies on T Cell Therapies to Treat Multiple Myeloma
Dr. Carl June's myeloma research publications in NEJM and Nature Medicine among the year’s ten most outstanding research papers.
Read more
